Investigational targeted therapies for the treatment of testicular germ cell tumors
Standard
Investigational targeted therapies for the treatment of testicular germ cell tumors. / Oing, Christoph; Kollmannsberger, Christian; Oechsle, Karin; Bokemeyer, Carsten.
in: EXPERT OPIN INV DRUG, Jahrgang 25, Nr. 9, 09.2016, S. 1033-43.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Investigational targeted therapies for the treatment of testicular germ cell tumors
AU - Oing, Christoph
AU - Kollmannsberger, Christian
AU - Oechsle, Karin
AU - Bokemeyer, Carsten
PY - 2016/9
Y1 - 2016/9
N2 - INTRODUCTION: Germ cell tumors (GCTs) are the most common malignancy among men aged between 15 to 45. Despite high cure rates of >90% over all GCTs, 3 to 5% of patients will still die of platinum-refractory disease. New systemic treatment options are needed to improve treatment success in this challenging setting.AREAS COVERED: To review targeted treatment options and preclinical developments in platinum-refractory GCTs, a comprehensive literature search of PubMed, Medline and scientific meeting abstracts on published clinical trials and reports on molecularly targeted approaches was conducted. Outcomes of platinum-refractory disease and of patients failing high-dose chemotherapy remain poor. Currently, no molecularly targeted treatment has shown clinically meaningful activity in unselected patient populations in clinical trials, but individual patients may achieve short-lived objective responses by treatment with sunitinib, brentuximab vedotin or imatinib. Targeted trials based on molecular selection of patients have not yet been performed.EXPERT OPINION: The limited activity of targeted agents in refractory GCT is disappointing. Assessment of druggable biomarkers and marker-stratified treatment may help individual patients, but is largely lacking. The low incidence and high curability of GCTs make the design of larger clinical trials difficult. The potential of novel agents, i.e. immune-checkpoint inhibitors, remains to be elucidated.
AB - INTRODUCTION: Germ cell tumors (GCTs) are the most common malignancy among men aged between 15 to 45. Despite high cure rates of >90% over all GCTs, 3 to 5% of patients will still die of platinum-refractory disease. New systemic treatment options are needed to improve treatment success in this challenging setting.AREAS COVERED: To review targeted treatment options and preclinical developments in platinum-refractory GCTs, a comprehensive literature search of PubMed, Medline and scientific meeting abstracts on published clinical trials and reports on molecularly targeted approaches was conducted. Outcomes of platinum-refractory disease and of patients failing high-dose chemotherapy remain poor. Currently, no molecularly targeted treatment has shown clinically meaningful activity in unselected patient populations in clinical trials, but individual patients may achieve short-lived objective responses by treatment with sunitinib, brentuximab vedotin or imatinib. Targeted trials based on molecular selection of patients have not yet been performed.EXPERT OPINION: The limited activity of targeted agents in refractory GCT is disappointing. Assessment of druggable biomarkers and marker-stratified treatment may help individual patients, but is largely lacking. The low incidence and high curability of GCTs make the design of larger clinical trials difficult. The potential of novel agents, i.e. immune-checkpoint inhibitors, remains to be elucidated.
KW - Journal Article
U2 - 10.1080/13543784.2016.1195808
DO - 10.1080/13543784.2016.1195808
M3 - SCORING: Journal article
C2 - 27286362
VL - 25
SP - 1033
EP - 1043
JO - EXPERT OPIN INV DRUG
JF - EXPERT OPIN INV DRUG
SN - 1354-3784
IS - 9
ER -